β2-Microglobulin as a biomarker in peripheral arterial disease: Proteomic profiling and clinical studies

Circulation

Volumn 116, Issue 12, 2007, Pages 1396-1403

  Wilson, Andrew M ^a   Kimura, Eiichiro ^a   Harada, Randall K ^a   Nair, Nandini ^a   Narasimhan, Balasubramanian ^a   Meng, Xiao Ying ^b   Zhang, Fujun ^b   Beck, Kendall R ^a   Olin, Jeffrey W ^c   Fung, Eric T ^b   Cooke, John P ^a,d  

^a STANFORD UNIVERSITY   (United States)

^b CIPHERGEN BIOSYSTEMS INC   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Beta 2 microglobulin; Inflammation; Peripheral vascular disease; Proteomics

Indexed keywords

BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; BIOLOGICAL MARKER;

AGED; ANGIOCARDIOGRAPHY; ANKLE BRACHIAL INDEX; ANTIBODY AFFINITY; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PRIORITY JOURNAL; PROTEOMICS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; WESTERN BLOTTING; ATHEROSCLEROSIS; BLOOD; COHORT ANALYSIS; EVALUATION; FEMALE; ISCHEMIA; LEG; MALE; MASS SPECTROMETRY; METHODOLOGY; MIDDLE AGED; PERIPHERAL VASCULAR DISEASE; PREDICTION AND FORECASTING; PROTEIN MICROARRAY; REPERFUSION INJURY; VALIDATION STUDY; VASCULARIZATION;

AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COHORT STUDIES; DIABETES COMPLICATIONS; FEMALE; HUMANS; ISCHEMIA; LEG; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PREDICTIVE VALUE OF TESTS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; REPERFUSION INJURY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 34548684818     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.106.683722     Document Type: Article

References (32)

1. Brevetti G, Oliva G, Silvestro A, Scopacasa F, Chiariello M. Prevalence, risk factors and cardiovascular comorbidity of symptomatic peripheral arterial disease in Italy. Atherosclerosis. 2004;175:131-138.
2. Criqui MH, Vargas V, Denenberg JO, Ho E, Allison M, Langer RD, Gamst A, Bundens WP, Fronek A. Ethnicity and peripheral arterial disease: the San Diego Population Study. Circulation. 2005;112:2703-2707.
3. Hayoz D, Bounameaux H, Canova CR. Swiss Atherothrombosis Survey: a field report on the occurrence of symptomatic and asymptomatic peripheral arterial disease. J Intern Med. 2005;258:238-243.
4. Hasimu B, Li J, Nakayama T, Yu J, Yang J, Li X, Hu D. Ankle brachial index as a marker of atherosclerosis in Chinese patients with high cardiovascular risk. Hypertens Res. 2006;29:23-28.
5. McDermott MM, Liu K, Greenland P, Guralnik JM, Criqui MH, Chan C, Pearce WH, Schneider JR, Ferrucci L, Celic L, Taylor LM, Vonesh E, Martin GJ, Clark E. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA. 2004;292:453-461.
6. Newman AB, Shemanski L, Manolio TA, Cushman M, Mittelmark M, Polak JF, Powe NR, Siscovick D; the Cardiovascular Health Study Group. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1999;19:538-545.
7. Newman AB, Tyrrell KS, Kuller LH. Mortality over four years in SHEP participants with a low ankle-arm index. J Am Geriatr Soc. 1997;45:1472-1478.
8. Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA. 2006;295:547-553.
9. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM, Hiatt WR. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317-1324.
10. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381-386.
11. Lefer AM. Role of selectins in myocardial ischemia-reperfusion injury. Ann Thorac Surg. 1995;60:773-777.
12. Oka RK, Szuba A, Giacomini JC, Cooke JP. A pilot study of L-arginine supplementation on functional capacity in peripheral arterial disease. Vasc Med. 2005;10:265-274.
13. Hiatt WR, Hirsch AT, Regensteiner JG, Brass EP; Vascular Clinical Trialists. Clinical trials for claudication: assessment of exercise performance, functional status, and clinical end points. Circulation. 1995;92:614-621.
14. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130:461-470.
15. Fung ET, Enderwick C. ProteinChip clinical proteomics: computational challenges and solutions. Biotechniques. 2002;(suppl):34-38, 40-41.
16. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001;98:5116-5121.
17. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A. 2002;99:6567-6572.
18. Hampel DJ, Sansome C, Sha M, Brodsky S, Lawson WE, Goligorsky MS. Toward proteomics in uroscopy: urinary protein profiles after radiocontrast medium administration. J Am Soc Nephrol. 2001;12:1026-1035.
19. Ishikawa I, Chikazawa Y, Sato K, Nakagawa M, Imamura H, Hayama S, Yamaya H, Asaka M, Tomosugi N, Yokoyama H, Matsumoto K. Proteomic analysis of serum, outflow dialysate and adsorbed protein onto dialysis membranes (polysulfone and PMMA) during hemodialysis treatment using SELDI-TOF-MS. Am J Nephrol. 2006;26:372-380.
20. Beckman JA, Jaff MR, Creager MA. The United States Preventive Services Task Force recommendation statement on screening for peripheral arterial disease: more harm than benefit? Circulation. 2006;114:861-866.
21. Braciale TJ. Antigen processing for presentation by MHC class I molecules. Curr Opin Immunol. 1992;4:59-62.
22. Acchiardo S, Kraus AP Jr, Jennings BR. Beta 2-microglobulin levels in patients with renal insufficiency. Am J Kidney Dis. 1989;13:70-74.
23. Takayama F, Miyazaki S, Morita T, Hirasawa Y, Niwa T. Dialysis-related amyloidosis of the heart in long-term hemodialysis patients. Kidney Int Suppl. 2001;78:S172-S176.
24. Alexanian R, Barlogie B, Fritsche H. Beta 2 microglobulin in multiple myeloma. Am J Hematol. 1985;20:345-351.
25. Cooper EH, Plesner T. Beta-2-microglobulin review: its relevance in clinical oncology. Med Pediatr Oncol. 1980;8:323-334.
26. Michalski JP, Daniels TE, Talal N, Grey HM. Beta2 microglobulin and lymphocytic infiltration in Sjogren's syndrome. N Engl J Med. 1975;293:1228-1231.
27. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
28. Saijo Y, Utsugi M, Yoshioka E, Horikawa N, Sato T, Gong Y, Kishi R. Relationship of beta2-microglobulin to arterial stiffness in Japanese subjects. Hypertens Res. 2005;28:505-511.
29. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation. 2005;112:976-983.
30. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998;97:425-428.
31. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397.
32. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.